Bristol Myers Squibb European Medicines Agency Validates Bristol Myers Squibbs Application for CAR T Cell Therapy Breyanzi in Relapsed or Refractory Large B-cell Lymphoma After First-Line Therapy marzo 25, 2022 47 0
